HONG KONG – Jiangsu Hengrui Medicine Co. Ltd. said the China National Drug Administration (CNDA) granted a conditional approval to its self-developed compound pyrotinib for treating HER2-positive breast cancer. The approval was based on clinical data from phase II studies, demonstrating China's effort in marketing domestic innovative drugs faster.